Paxlovid received emergency use authorization from the U.S. Food and Drug Administration in December 2021 as an oral antiviral agent for the treatment of symptomatic, non-hospitalized adults with mild to moderate COVID-19 infection who are at high risk for progression to severe disease. Patients ...
Since COVID-19 first spread rapidly around the world in 2020, we have significantly more options to reduce the symptoms and severity of the virus. COVID-19 symptoms usually begin in the first five days after exposure and can last up to 14 days. For many people, over-the-counter medicatio...